Hcw Biologics Stock Today
| HCWB Stock | USD 1.28 0.05 3.76% |
Performance4 of 100
| Odds Of DistressOver 85
|
HCW Biologics is trading at 1.28 as of the 8th of May 2024, a -3.76 percent decrease since the beginning of the trading day. The stock's open price was 1.33. HCW Biologics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for HCW Biologics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 14th of May 2023 and ending today, the 8th of May 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 20th of July 2021 | Category Healthcare | Classification Health Care |
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company was incorporated in 2018 and is headquartered in Miramar, Florida. The company has 37.82 M outstanding shares of which 7.63 K shares are currently shorted by private and institutional investors with about 0.38 trading days to cover. More on HCW Biologics
Moving together with HCW Stock
| 0.74 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
| 0.72 | CRL | Charles River Labora Financial Report 9th of May 2024 | PairCorr |
| 0.63 | IQV | IQVIA Holdings | PairCorr |
Moving against HCW Stock
| 0.7 | GRFS | Grifols SA ADR | PairCorr |
| 0.53 | SHC | Sotera Health | PairCorr |
| 0.49 | GNFT | Genfit | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
HCW Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. HCW Biologics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding HCW Biologics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering HCW Biologics report their recommendations after researching HCW Biologics' financial statements, talking to executives and customers, or listening in on HCW Biologics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering HCW Biologics. The HCW consensus assessment is calculated by taking the average forecast from all of the analysts covering HCW Biologics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to HCW Biologics' liquidity, profitability, solvency, and operating efficiency, HCW Biologics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in June. Financial strength of HCW Biologics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HCW Biologics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to HCW Biologics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand HCW Biologics' financial leverage. It provides some insight into what part of HCW Biologics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HCW Biologics (HCWB) is traded on NASDAQ Exchange in USA. It is located in 2929 North Commerce Parkway, Miramar, FL, United States, 33025 and employs 45 people. HCW Biologics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 48.41 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate HCW Biologics's market, we take the total number of its shares issued and multiply it by HCW Biologics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. HCW Biologics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 37.82 M outstanding shares of which 7.63 K shares are currently shorted by private and institutional investors with about 0.38 trading days to cover.
HCW Biologics currently holds about 32.41 M in cash with (22.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9.
Check HCW Biologics Probability Of Bankruptcy
Ownership AllocationHCW Biologics has a total of 37.82 Million outstanding shares. HCW Biologics secures noticeable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check HCW Ownership Details
HCW Stock Price Odds Analysis
What are HCW Biologics' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of HCW Biologics jumping above the current price in 90 days from now is about 81.72%. The HCW Biologics probability density function shows the probability of HCW Biologics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days HCW Biologics has a beta of -0.3817. This usually indicates as returns on the benchmark increase, returns on holding HCW Biologics are expected to decrease at a much lower rate. During a bear market, however, HCW Biologics is likely to outperform the market. Additionally, hCW Biologics has an alpha of 0.2706, implying that it can generate a 0.27 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of HCW Biologics to move above the current price in 90 days from now is about 81.72 (This HCW Biologics probability density function shows the probability of HCW Stock to fall within a particular range of prices over 90 days) .
HCW Stock Institutional Holders
Institutional Holdings refers to the ownership stake in HCW Biologics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of HCW Biologics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing HCW Biologics' value.| Instituion | Recorded On | Shares | |
| Tower Research Capital Llc | 2023-12-31 | 5.7 K | |
| Focused Wealth Strategies, Inc. | 2023-12-31 | 1000 | |
| Ubs Group Ag | 2023-12-31 | 635 | |
| Royal Bank Of Canada | 2023-12-31 | 296 | |
| Wells Fargo & Co | 2023-12-31 | 138 | |
| Jpmorgan Chase & Co | 2023-12-31 | 83.0 | |
| Bank Of America Corp | 2023-12-31 | 11.0 | |
| Vanguard Group Inc | 2023-12-31 | 205.1 K | |
| Hightower Advisors, Llc | 2023-12-31 | 179.8 K | |
| Honkamp Krueger Financial Services Inc | 2024-03-31 | 179.8 K | |
| Geode Capital Management, Llc | 2023-12-31 | 134.4 K |
HCW Biologics Historical Income Statement
HCW Biologics Income Statement is one of the three primary financial statements used for reporting HCW's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of HCW Biologics revenue and expense. HCW Biologics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, HCW Biologics' Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 3.9 M, whereas Net Interest Income is projected to grow to (360 K). View More FundamentalsHCW Stock Against Markets
Picking the right benchmark for HCW Biologics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in HCW Biologics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for HCW Biologics is critical whether you are bullish or bearish towards HCW Biologics at a given time. Please also check how HCW Biologics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in HCW Biologics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Financial Widgets Now
Financial WidgetsEasily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
| All Next | Launch Module |
HCW Biologics Corporate Management
Elected by the shareholders, the HCW Biologics' board of directors comprises two types of representatives: HCW Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HCW. The board's role is to monitor HCW Biologics' management team and ensure that shareholders' interests are well served. HCW Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HCW Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hing Wong | CEO, Founder | Profile | |
| Lee Flowers | Senior Development | Profile | |
| Peter Rhode | Chief Operations | Profile | |
| Nicole Esq | Vice Affairs | Profile |
How to buy HCW Stock?
Before investing in HCW Biologics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in HCW Biologics. To buy HCW Biologics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of HCW Biologics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase HCW Biologics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located HCW Biologics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased HCW Biologics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as HCW Biologics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy HCW Stock please use our How to Invest in HCW Biologics guide.
Already Invested in HCW Biologics?
The danger of trading HCW Biologics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of HCW Biologics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than HCW Biologics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile HCW Biologics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether HCW Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of HCW Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hcw Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hcw Biologics Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HCW Biologics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for HCW Stock analysis
When running HCW Biologics' price analysis, check to measure HCW Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HCW Biologics is operating at the current time. Most of HCW Biologics' value examination focuses on studying past and present price action to predict the probability of HCW Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HCW Biologics' price. Additionally, you may evaluate how the addition of HCW Biologics to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is HCW Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. If investors know HCW will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HCW Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.70) | Revenue Per Share 0.079 | Quarterly Revenue Growth (0.01) | Return On Assets (0.43) | Return On Equity (0.98) |
The market value of HCW Biologics is measured differently than its book value, which is the value of HCW that is recorded on the company's balance sheet. Investors also form their own opinion of HCW Biologics' value that differs from its market value or its book value, called intrinsic value, which is HCW Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HCW Biologics' market value can be influenced by many factors that don't directly affect HCW Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HCW Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.